(95% CI 91–94.7%, $p < 0.0001$) when both PLT and ALB were in normal range.

Conclusions US alone is not a reliable imaging modality for diagnosing cACLD. In suspected cases, TE should be carried out to determine the severity of hepatic fibrosis before a diagnosis of cACLD is made.

PWE-42 MENTAL HEALTH READMISSIONS ARE INCREASED IN TRANSPLANT-FREE SURVIVORS OF ACUTE LIVER FAILURE

¹Mhairi C Donnelly*, ²Linda Williams, ²Nazir Lone, ¹Kenneth J Simpson. ¹Royal Infirmary of Edinburgh, Edinburgh, UK; ²University of Edinburgh, Edinburgh, UK

10.1136/gutjnl-2021-BSG.232

Introduction Patients surviving acute liver failure (ALF) without transplantation (spontaneous survivors; SS) are at increased risk of later death and readmission to hospital. Most cases of ALF in Scotland are managed in the Scottish Liver Transplant Unit (SLTU) and are due to paracetamol overdose (POD). The aim of this work was to analyse mental health readmissions in Scottish ALF SS, compared with comparator cohorts.

Methods The index cohort (SLTU SS) consisted of patients admitted with severe acute liver injury or failure between 01/11/1992 and 31/12/2014 who survived to hospital discharge without transplantation. Patients were identified from the SLTU ALF database. Control cohorts were: age, sex and post-code sector matched general population controls, patients admitted to hospital following POD in Scotland and not transferred to SLTU, patients admitted to Scottish intensive care units as non-surgical emergency admissions (SICSAG cohort) and patients surviving ALF with transplantation. Data related to mental health readmissions following discharge from the index admission were derived from the SMR04 database.

Results The SLTU SS cohort consisted of 708 patients (80.2% POD). 25.6% of the SLTU SS had at least one mental health readmission (29.5% of POD SS versus 10.0% of non-POD SS).

The SLTU SS were more likely to experience a mental health readmission compared with the matched control cohort (adjusted SHR 11.23, 95% CI 8.55, 14.71), paracetamol overdose cohort (adjusted SHR 1.25, 95% CI 1.04, 1.51) and the SICSAG cohort (adjusted SHR 2.76, 95% CI 1.99, 3.82).

The adjusted relative rate of mental health readmissions was also higher in the SLTU SS compared with the matched

control cohort (10.63, 95% CI 7.58, 14.90), the paracetamol overdose cohort (2.90, 95% CI 2.23, 3.77) and the SICSAG cohort (5.91, 95% CI 3.54, 9.88). In the SLTU SS, POD aetiology and prior mental health admissions were predictors of later mental health readmissions.

The main psychiatric diagnosis in the SLTU SS was depressive disease (27.4%) compared with alcohol misuse (27.3%) in the matched controls, depressive disease (30.2%) in the paracetamol overdose controls and alcohol misuse (32.1%) in the SICSAG controls.

A comparative mental health morbidity analysis was not possible in the ALF survivors with transplant, as <10 post-transplant patients had any post-discharge mental health readmissions.

Conclusions Scottish ALF SS are at increased risk of mental health readmissions following discharge. The risk of readmission is higher in those with POD ALF compared with POD without ALF. Patients surviving ALF without transplant are currently discharged without follow up. This work suggests that psychiatric follow up – particularly in those with POD ALF – is warranted to reduce the burden of mental health readmissions.

PWE-43 SARS-COV-2 ONE YEAR ON – THE WORRYING IMPACT ON EARLY DETECTION OF LIVER CANCERS

^{1,2}Daniel Geh*, ^{1,2}Robyn Watson, ^{2,3}Stuart McPherson, ^{2,3}Steven Masson, ^{2,3}Jessica Dyson, ^{2,3}Mhairi Donnelly, ^{2,3}Louise MacDougall, ^{2,3}Preya Patel, ^{3,4}John Hammond, ^{3,5}Paul Turner, ^{3,5}Tim Hoare, ^{3,5}Kirsty Anderson, ^{3,5}Michael McNeil, ^{3,4}Gourab Sen, ^{3,4}Prof Steven White, ^{3,4}Jeremy French, ^{3,4}Stuart Robinson, Lucy Walker, ^{1,2}Ms Misti McCain, ⁶Nick Wadd, ⁷Syed Asghar, ^{3,8}Lavanya Mariappan, ^{3,8}Jane Margetts, ³Yvonne Bury, ³Shreya Raman, ³Antony Darne, ³Beate Haugk, ^{3,5}John Scott, ^{3,5}Peter Littler, ^{3,4}Derek M Manas, ^{1,2,3}Helen L Reeves. ¹Translational and Clinical Research Institute, Newcastle University; ²Department of Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust; ³Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne Hospitals NHS Foundation Trust; ⁴Department of Surgery, Newcastle upon Tyne Hospitals NHS Foundation Trust; ⁵Department of Radiology, Newcastle upon Tyne Hospitals NHS Foundation Trust; ⁶Department of Oncology, South Tees Hospital NHS Foundation Trust; ⁷Department of Oncology, Newcastle upon Tyne Hospitals NHS Foundation Trust; ⁸Department of Oncology, Cumberland Infirmary, North Cumbria Integrated Care NHS Foundation Trust

10.1136/gutjnl-2021-BSG.233

Background In Northern England new primary liver cancer (PLC) diagnoses have increased by 10-15% year on year. We evaluated the impact of the SARS-CoV-2 pandemic.

Method In this retrospective, observational, regional study we evaluated 455 new PLC patients referred to the Newcastle-

Abstract PWE-43 Figure 1

upon-Tyne NHS Foundation Trust, comparing the 12 months directly preceding the pandemic (YR1) to the first 12 months of it (YR2). Variables included; presentation, etiology, stage, treatment and SARS-CoV-2 infection.

Results New referrals with hepatocellular carcinoma (HCC) fell for the 1st time in 15 years in YR2 (35%; 125 in YR2 from 190 in YR1; Fig1A), with more presenting symptomatically. This was particularly striking for NAFLD patients (surveillance/incidental/symptomatic 32/55/13% in YR1 compared to 26/41/33% in YR2, $p=0.028$, Fig1B). Tumour size was greater in YR2 (med 44 vs 37 mm; $p=0.0165$, Fig1C), with 6 patients experiencing spontaneous hemorrhage in YR2. Despite challenges in YR2, patients received treatments appropriate for stage, in accordance with NHS waiting times. 11/125 (9%) acquired SARS-CoV-2. None of these patients died due to their SARS-CoV-2 infection. Cases presenting with intrahepatic cholangiocarcinoma were also reduced in YR2, but less so (64 vs 76), with the commonest mode of presentation unchanged (symptomatic ~75%).

Conclusion The tragic consequences of the SARS-CoV-2 pandemic are evident for patients in our region – whose cancers are now more commonly presenting symptomatically. In our series, 9% (11/125) of patients contracted SARS-CoV-2, of whom 3 subsequently died of advanced disease rather than SARS-CoV-2. At least 35% of our anticipated patients with HCC are ‘missing’. If routine activities, including HCC surveillance, are not re-instituted and patients encouraged to attend, it is likely that they too will present with symptomatic advanced HCC.

PWE-44 RESOURCE UTILISATION IN VARICEAL SURVEILLANCE PROGRAM DELIVERED WITHIN A NURSE-LED STABLE CIRRHOSIS CLINIC

Muhammad Saleem*, Mohamed Elnagar, Alison Beard, Samantha Whyld, Andrew Austin.
Royal Derby Hospital, Derby, UK

10.1136/gutjnl-2021-BSG.234

Introduction Bleeding from GOV represents 30% of total acute upper GI haemorrhage with mortality of up to 20% at initial presentation. Whilst mortality in Child A disease should be <10%, each emergency presentation is expensive. The GIRFT report recommends developing a database for cirrhosis in order to ensure a systematic approach to varices surveillance, something we have delivered via a Nurse led stable cirrhosis clinic since 2016. While BSG guidelines recommended screening for all patients with cirrhosis or PHT, we have adopted Baveno VI consensus workshop criteria ($TE < 20$ kPa or platelet count > 150) to safely avoid gastroscopy in this cohort. Grade 2/3 varices required primary prophylaxis with banding (VBL) or non-selective beta blockers (NSBB). In 2016, prophylaxis for grade 1 varices was not recommended.

Methods We conducted a retrospective review for all the cirrhotic patients seen in our nurse-led stable cirrhosis clinic during the first year of its establishment

Results In 2016, a total of 53(40 male) cirrhotic patients were reviewed in the clinic (ALD 25, NASH 9, other 20). Other aetiologies included HCV, PBC and HFE-related cirrhosis. Only 3 patients had Child Pugh B with the rest having Child A disease. No patient had ever suffered variceal bleeding. 26/53 (49%) patients met the exclusion criteria set by Baveno VI consensus and would have avoided OGD. 12/26 had their

index OGD which had been ordered prior to the instigation of the nurse-led clinic and reassuringly none showed varices. Screening was indicated for the remaining 27 patients. One patient passed away before his surveillance appointment. Grade I OV were diagnosed in 13/27 (48%) patients, of whom 7 inappropriately received NSBB and the remainder had follow up OGD at one year. Grade II varices were identified in 2/27 (7.5%) and band ligation performed. In the remaining 11/27 no varices were found and with annual improvements in fibroscan measurements only 5/11 required follow up OGD. None of the patients had variceal bleed in follow up 5 year period.

Conclusions Variceal screening is an important step in identifying high risk varices. By following Baveno VI criteria in this cohort, we have conformed the potential to reduce demand for OGD by around 50% for immediate OGD and another 50% of the remainder whose fibroscan results improve with abstinence from alcohol without subsequent bleeding events. Our review also shows an opportunity to improve resource utilisation by refreshing adherence to the existing guidelines.

PWE-45 BACTERAEMIA, SEPSIS, AND ANTIBIOTIC RESISTANCE IN AUSTRALIAN PATIENTS WITH CIRRHOSIS: A POPULATION-BASED STUDY

^{1,2}Amy Johnson*, ³Isanka Ratnasekera, ³Katharine Irvine, ^{4,5}Andrew Henderson, ^{1,2}Elizabeth Powell, ⁶Patricia Valery. ¹Princess Alexandra Hospital, Department of Gastroenterology and Hepatology, Brisbane, Australia; ²Centre for Liver Disease Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia; ³Mater Research Institute, Translational Research Institute, The University of Queensland, Brisbane, Australia; ⁴Infection Management Services, Princess Alexandra Hospital, Brisbane, Australia; ⁵University of Queensland Centre for Clinical Research, Herston, Brisbane, Australia; ⁶QIMR Berghofer Medical Research Institute, Brisbane, Australia

10.1136/gutjnl-2021-BSG.235

Introduction Multiple factors predispose patients with cirrhosis to sepsis and/or bacteraemia and this has a high mortality rate. Within different geographic regions there are marked differences in the prevalence of infection with multidrug resistant organisms (MDRO). This study examined risk factors for and outcomes of sepsis/bacteraemia in Australian public hospital admissions with cirrhosis over the last decade, along with the bacterial pathogens responsible and their antibiotic susceptibility profiles.

Methods A population-based retrospective cohort study was conducted from 1 January 2008 to 31 December 2017. Hospital admissions for patients with a diagnosis of cirrhosis were categorized by the presence or absence of sepsis/bacteraemia. Clinical and socio-demographic information including cirrhosis aetiology, complications and comorbidities, and in-hospital mortality were examined using bivariate and multivariate analyses. In patients with bacteraemia, the type and prevalence of bacteria and antibiotic resistance was assessed.

Results Sepsis/bacteraemia was present in 3,951 of 103,165 hospital admissions with a diagnosis of cirrhosis. Factors associated with sepsis/bacteraemia included disease aetiology, particularly primary sclerosing cholangitis (adj-OR=15.09, 95%CI 12.24-18.60), alcohol (adj-OR=2.90, 95%CI 2.71-3.09), Charlson co-morbidity index ≥ 3 (adj-OR=3.54, 95%CI 3.19-3.93), and diabetes (adj-OR=1.87, 95%CI 1.74-2.01). Overall case-fatality rate among admissions with sepsis/bacteraemia was 27.7% (95%CI, 26.3%-29.1%) vs 3.0% (95%CI, 28.9%-31.1%) without sepsis/bacteraemia. Patients with sepsis/